Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.48 |
| ▸ | MMP1 | P03956 | 9/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675288 | 1.00 | CCR2 (0.48) | CCR2MMP1MMP3MMP2MMP7 | |
| Hydrochloric Acid SCHEMBL25344436 | 0.88 | CCR2 (0.60) | CCR2MMP1MMP3MMP2MMP7 | |
| Hydrochloric Acid SCHEMBL25344442 | 0.88 | CCR2 (0.60) | CCR2MMP1MMP3MMP2MMP7 | |
| Hydrochloric Acid SCHEMBL25344446 | 0.88 | CCR2 (0.60) | CCR2MMP1MMP3MMP2MMP7 | |
| SCHEMBL12331694 | 0.86 | CCR2 (0.50) | CCR2MMP1MMP3MMP2MMP7 | |
| SCHEMBL18675287 | 0.86 | CCR2 (0.50) | CCR2MMP1MMP3MMP2MMP7 | |
| SCHEMBL5763039 | 0.83 | MASP2 (0.42) | — | |
| SCHEMBL5761726 | 0.83 | MASP2 (0.42) | — | |
| SCHEMBL23314757 | 0.80 | CCR2 (0.41) | CCR2MMP1MMP3MMP2MMP7 | |
| SCHEMBL17282634 | 0.80 | CCR2 (0.45) | CCR2MMP1MMP3MMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CCR2 4502/4885MMP1 330/4885MMP3 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.